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Abstract
Until recently, culture, microscopy, and serology have been the available methods for the diagnosis of
coccidioidomycosis. While Coccidioides is frequently isolated by culture, special precautions must be
taken because of the risk of laboratory infection and because Coccidioides is on the Select Agent list.
Serology is useful but the sensitivity remains lower than desired. A commercially available test for
coccidioidal galactomannan antigenuria now exists and appears useful for immunocompromised hosts
with severe disease. Polymerase chain reaction assays targeting specific coccidioidal genes have
demonstrated utility but are not commercially available. Moreover, their sensitivity and the best
sample type remain unestablished.
Introduction and context
The endemic region for coccidioidomycosis is restricted
to the Western Hemisphere. Almost all coccidioidal
infections are due to inhalation of arthroconidia, 2-5 µm
barrel-shaped spores that dislodge from hyphae and
become airborne [1]. A full 60% of all coccidioidal infec-
tions are completely asymptomatic, with only the expres-
sionofspecificdelayed-typehypersensitivityasamarkerfor
infection [2]. Unfortunately, coccidioidal skin tests are not
currently available in the US.
The other 40% of individuals with acute pulmonary
coccidioidomycosis present with a syndrome similar to
abacterialcommunity-acquiredpneumonia,withcough,
pleuritic chest pain, and fever. In one recent study per-
formed in the coccidioidal endemic region, coccidioido-
mycosis was misidentified in approximately 29% of
individuals as a bacterial process [3]. In fewer than 1% of
all individuals infected, disseminated clinical infection
occursoutsideofthethoraciccavity.Thismostcommonly
presents as a skin or soft tissue lesion, osteomyelitis, or
meningitis.
Coccidioidomycosis is now recognized to be caused by
two distinct species, Coccidioides immitis and C. posadasii.
The former appears to be geographically limited to the
southern portion of California and Northern Mexico
while the latter occurs in all geographic areas [4]. At this
time, the presentation of disease and diagnosis do not
appear to differ between the two species.
Available diagnostic tests
For the past several decades three modalities – culture,
microscopy, and serology – have been the mainstays of
specific diagnosis of coccidioidomycosis.
Culture
Unlike other endemicfungi,Coccidioides grows readilyon
a variety of culture media at 35°C and is usually visually
apparent in 2-7 days. It can be presumptively identified
based on its early lack of pigmentation and the later
presence of septate hyphae with barrel-shaped arthro-
conidia on microscopic examination [5]. A proprie-
tary nucleic acid chemiluminescent probe (AccuProbe,
Gen-Probe, Inc., San Diego, CA, USA) allows rapid,
specific identification once visible growth has occurred
[6]. A major drawback of culture is the extreme danger
of Coccidioides in the laboratory. Several documented
accidental exposures have occurred and Stevens and
colleagues [7] have recently outlined their approach to
managing such events. Moreover, Coccidioides is listed
as a ‘Select Agent’ of bioterrorism [8]. Because of these
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Microscopy
Coccidioides can be identified directly in fresh respiratory
secretions using potassium hydroxide, calcifluor, and
Papanicolaou. However, the sensitivity of these methods
is relatively low [9,10]. The diagnosis can also be esta-
blished in fixed tissue using a variety of stains, including
hematoxylin-eosin and Gomori methenamine-silver. The
pathognomonic structure is the spherule.
Serology
Serologic tests for the diagnosis of coccidioidomycosis
are time honored and perhaps the most frequently
employed assays for the diagnosis of coccidioidomycosis
[1,11]. Smith and colleagues established the modern use
of coccidioidal serology with the development of the
tube precipitin (TP) and complement fixation (CF)
assays [12]. Each relies on a specific antigen. For TP,
this is now known to be a heat-stable 120 kDa b-
glucosidase [13], while for CF it is a heat-labile chitinase
[14]. The IDTP and IDCF are variants of these assays that
employ immunodiffusion (ID) in agar. All are very
specific and, at least from early studies, relatively
sensitive [12]. The TP and IDTP assays conform to an
immunoglobulin (Ig)M reaction and are positive early in
illness and, at times, during recurrence. The CF and IDCF
assays become positive usually after 2-3 weeks of illness,
conform to an IgG reaction, and their titer has prognostic
implications, with high titers portending severe or disse-
minated disease. In persons who resolve their clinical
illness, both reactions become negative over time.
Recent advances
Serology
Since the 1990s, a proprietary enzyme-linked immuno-
sorbant assay (Premier EIA, Meridian Diagnostics, Inc.,
Cincinnati, OH, USA) has been widely employed in the
endemic region. Martins and colleagues [15] initially
compared this assay to standard TP and CF assays as well
as the less specific latex agglutination assay and, after
combining the IgM and IgG enzyme immunoassay (EIA)
results, found that the specificity was 98.5% and the
sensitivity was 95.5%. Kaufman and coworkers [16]
examined 47 specimens from persons with confirmed
coccidioidomycosis and a positive IDCF and found all
were also positive for either IgM or IgG using the EIA;
however, 12 of 345 samples from patients with other
pulmonary infections were also EIA positive. In another
study, among 41 patients with culture-confirmed cocci-
dioidomycosis who had three serologic tests performed,
the CF was positive in 23 (56%), the IDCF in 29 (71%),
and the EIA in 34 (81%) [17]. In six (15%) patients, all
serologic tests were negative. Blair and colleagues [18]
examined immunocompromised patients and found,
as expected, that serologic tests were less likely to be
positive than among normal hosts. They subsequently
examined patients with an isolated IgM EIA reaction and
were able to confirm a diagnosis of coccidioidomycosis
by other means in all cases [20]. Hence, while there is
lingering concern regarding the specificity of the Premier
EIA, particularly the IgM (D Pappagianis, personal
communication), published reports suggest that it is
sensitive. Another proprietary EIA (Coccidioides DxSelect™
on its performance parameters.
Detection of antigenuria
During the 1980s, assays were developed to detect
coccidioidal circulating antigen [20-22]. Unfortunately,
these never achieved the sensitivity required for clinical
use. However, Kuberski and coworkers [23] recently
reported several instances where a commercially avail-
able assay for detecting Histoplasma capsulatum antigen-
uria was found to be positive in samples from patients
with coccidioidomycosis. This led to the development of
a specific assay for Coccidioides [24]. To develop this test,
antibody was raised in rabbits immunized to galacto-
mannan isolated from the mycelial stage of clinical
isolates of Coccidioides and used in an enzyme-linked
immunosorbent assay. The assay detected as little as
0.03 ng/ml of Coccidioides galactomannan. Among
24 patients with coccidioidomycosis, most with under-
lying immunosuppression and severe disease, 17 (71%)
had a positive test. The Histoplasma antigenuria assay
was positive in 14 of these patients while coccidioidal
antigenuria was detected in 3 of 28 (11%) samples
from patients with other endemic mycoses, including
two with histoplasmosis, confirming the problem of
cross-reactivity.
Genomic analysis
Tests based on detection of the genetic fingerprint of
the fungus offer the promise of rapidity and specificity
without the requirement of growing the organism or
relying on the response of the host. While several
investigators have demonstrated the feasibility of such
approaches, no such tests are currently commercially
available.
Because of high copy number and variability among
fungal species, one region of particular interest in such
analyses has been the 18S ribosomal rRNA genomic
sequence (rDNA). Johnson and coworkers [25] used
primers for this region in a polymerase chain reaction
(PCR) to determine if the coccidioidal rDNA genome
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Focus Diagnostics, Inc., Cypress, CA, USA) became
available in 2006. There are no published studiescould be detected in human sera obtained from patients
with suspected coccidioidomycosis. Among 94 samples
tested, all originally submitted for coccidioidal serologic
testing, 6 demonstrated an appropriately sized 239 base-
pair DNA band. Using these same primers, Japanese
investigators wererecentlyable todetect thisbandinDNA
extracted from formalin-fixed paraffin-embedded lung
tissue from four patients with coccidioidomycosis [26].
Binnicker and colleagues [27] employed real-time PCR
with primers amplifying a 170 base-pair region in the
ITS2 (internal transcribed spacer 2) region of the rDNA
genome to examine 266 respiratory specimens sub-
mitted for fungal culture. Most of these specimens were
submitted from within the coccidioidal endemic region.
Among 20 samples that were culture positive for
Coccidioides, 16 were positive by real-time PCR, com-
pared to none of the culture negative samples, yielding a
sensitivity of 98% and a specificity of 100%. In addition,
real-time PCR was positive in all 47 samples found to
demonstrate Coccidioides by histopathological examina-
tion, whereas it was positive in 17 cases among 101
where histopathology was negative.
Bialek and colleagues [28] have performed several
studies using PCR to detect the unique coccidioidal
gene, antigen-2/proline rich antigen (Ag2/PRA) [29,30],
which exists as only one copy in the genome. They
initially correctly identified 120 isolates of C. posadasii
from Mexico using both conventional nested and real-
time PCR and found no false positives [28]. Since then,
Brazilian investigators were able to apply nested PCR to
a respiratory sample from a patient with pulmonary
coccidioidomycosis and detected the appropriate 349
base-pair product of Ag2/PRA in the sample [31].
Implications for clinical practice
The concerns regarding the specificity of Premier EIA
compared to the older serologic assays are likely to
persist. For the present, a TP or IDTP should be obtained
for all positive IgM EIA tests, and a CF or IDCF assay
should be obtained and titrated in all instances of a
positive EIA IgG. However, experts recommend that the
EIA is very sensitive and other assays need not be
obtained if it is negative [32]. It is also clear that a
serologic test may be negative during active coccidioi-
domycosis and serology should not be wholly relied
upon in such instances.
A critical question regarding coccidioidal antigenuria is
its sensitivity for different syndromes of coccidioidomy-
cosis. While preliminary data suggest it is helpful for
those who are highly immunocompromised and for
those with widely disseminated disease, it is not clear if it
will be useful for those with less severe illness and for
those with disease confined to the thoracic cavity. In
addition, there is documented cross-reactivity, particu-
larly in patients with histoplasmosis, which may reduce
its diagnostic utility.
Finally, while genomic detection of Coccidioides is promi-
sing,muchmoreworkonsensitivityandsampletypeneeds
to be done. Moreover, PCR has been notoriously difficult
to perform in clinical laboratories because of the risk of
contamination. These issues will need to be resolved prior
to these assays becoming clinically available.
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